The Use of FOLFIRINOX as First-Line Treatment for Metastatic Pancreatic Adenocarcinomaenglish
Adult patients with MPA who have not received prior systemic treatment for it.
Intended Guideline Users
Clinicians and healthcare providers involved in the management of patients with MPA.
Does FOLFIRINOX (folinic acid, 5FU, irinotecan and oxaliplatin) improve overall survival, progression free survival (PFS), response rate, and/or quality of life (QOL), with acceptable levels of adverse events, for adult patients with metastatic pancreatic adenocarcinoma (MPA)?